Monday, May 16, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

FDA Challenge: Infectious Diseases NGS Diagnostics for Biothreats

by Global Biodefense Staff
August 19, 2018
Sequencing Medical Research
precisionFDA ID-NGS Diagnostics Biothreat Challenge
Credit: FDA

To encourage the development and improvement of Infectious Diseases Next-Generation Sequencing (ID-NGS) analytical methods, precisionFDA – the community platform for NGS assay evaluation and regulatory science exploration – has launched the precisionFDA CDRH Infectious Disease NGS Diagnostics Biothreat Challenge.

Professional and citizen scientists are invited to test their bioinformatics skills and software tools in a challenge to identify pathogens from the FDA-ARGOS database within host samples using NGS short-read data.

The focus of this challenge is to enable tool developers to test their algorithms on blinded mock-clinical and in silico metagenomics samples using provided regulatory-grade reference genomes from the FDA-ARGOS database. This will enable the community to look at bioinformatics pipeline performance using a fixed reference genome data standard. The challenge will help familiarize precisionFDA users with the agency’s innovative FDA-ARGOS database resource (www.fda.gov/argos).

The challenge is open now through October 4, 2018.

About FDA-ARGOS

A publicly available database for Reference Grade microbial Sequences, called FDA-ARGOS, was established by the FDA and collaboraters in 2014. With funding support from FDA’s Office of Counterterrorism and Emerging Threats (OCET) and DoD, the FDA-ARGOS team are initially collecting and sequencing 2000 microbes that include biothreat microorganisms, common clinical pathogens and closely related species.

Currently, FDA-ARGOS microbial genomes are typically generated in 3 phases:

  • Phase 1 entails collection of a previously identified microbe and nucleic acid extraction
  • Phase 2, the microbial nucleic acids are sequenced and de novo assembled using Illumina and Pac Biosequencing platforms at the Institute for Genome Sciences at the University of Maryland (UMD-IGS)
  • Phase 3, the assembled genomes are vetted by an ID-NGS subject matter expert working group consisting of FDA personnel and collaborators and the data are deposited in NCBI databases

Manufacturers who develop sequence-based test to identify infectious agents and/or to detect resistance or virulence markers can use FDA-ARGOS to advance their development programs and to support the regulatory science review of such test. For example, FDA-ARGOS can be used as a tool for in-silico (computer simulation) data analysis.

Additional Resources

  • In Vitro Diagnostics
  • Access the FDA-ARGOS Database @ NCBI
  • Guidance Document: Infectious Disease Next Generation Sequencing Based Diagnostic Devices: Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers – Draft Guidance for Industry and Food and Drug Administration Staff

Source: Food and Drug Administration

Tags: Bioinformatics

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools
Biodetection

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022
Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization
Biodetection

Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization

March 19, 2022
Bruker Enables High-Throughput Multiplex HTS  in Support of Drug Discovery
Biodetection

Bruker Enables High-Throughput Multiplex HTS in Support of Drug Discovery

February 7, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC